Tagatose

Summary

Tagatose (CHEMBL1236183) is a phase-3 clinical-stage small molecule; indicated across 1 condition including type 2 diabetes mellitus.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 5
• Chemistry: 180.16 Da · C6H12O6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1236183
Name	Tagatose
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	92092
ChEBI	CHEBI:47693
Molecular formula	C6H12O6
Molecular weight	180.16
InChIKey	BJHIKXHVCXFQLS-PQLUHFTBSA-N

SMILES: C([C@H]([C@@H]([C@@H](C(=O)CO)O)O)O)O

IUPAC name: (3S,4S,5R)-1,3,4,5,6-pentahydroxyhexan-2-one

ChEBI definition: The straight-chain keto form of D-tagatose.

Also known as: D-tagatose, Naturlose, Tagatose, TAGATOSE, D-(-)-TAGATOSE, D-(-)-Tagatose

Patent coverage: 8,759 distinct patent families (30,595 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
type 2 diabetes mellitus	3	MONDO:0005148	MONDO:0005148

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
Not specified	3
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00955747	PHASE3	COMPLETED	Naturlose (D-Tagatose) Efficacy Evaluation Trial
NCT00961662	PHASE2	COMPLETED	A Clinical Study to Evaluate the Effect of Naturlose (Tagatose)
NCT02776722	Not specified	UNKNOWN	Meta-analyses of the Effect of ‘Catalytic’ Doses of Fructose and Its Epimers on Carbohydrate Metabolism
NCT04327245	Not specified	COMPLETED	To Compare the Effects of Non-nutritive Sweeteners Intake in Woman With Insulin Resistance
NCT06920641	Not specified	COMPLETED	Effects of Tagatose on Glycemic Response and Gastrointestinal Microbiota in Healthy Adults

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).